When to Switch a Drug Class in Psoriasis Treatment

EP: 1.Choosing the Right Psoriasis Treatment: Tailoring Therapy to Patient Characteristics

EP: 2.Screening for PsA and Selecting Right Biologic Therapy

EP: 3.Biologics for Psoriasis: TNF Blockers

EP: 4.Benefits of IL Therapies in Patients with PP

EP: 5.Understanding Comorbidities: Impact on Biologic Treatment Selection

EP: 6.Unraveling Boxed Warnings: Exploring/Examining Risks in Biologic Treatment Classes

EP: 7.Infectious Diseases and Biologic Treatment Selection

EP: 8.Understanding Biologics for Patients With IBD

EP: 9.Exploring Innovation: Recent Approvals and Novel Approaches to Psoriasis Treatment

EP: 10.Warnings and Precautions for Newer Psoriasis Treatments

Now Viewing

EP: 11.When to Switch a Drug Class in Psoriasis Treatment

Dermatologists discuss their approach to managing patients who have experienced treatment failure. They debate whether to switch to a different class of drug or remain within the same class based on factors such as primary versus secondary failure and individual patient response. They also mention specific drugs within the class, like bimekizumab, and discuss the efficacy and considerations of different options. The conversation highlights the complexity of decision-making in dermatology regarding treatment selection for patients who have not responded to TNF blockers.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.